Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London.  Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.   

Benefits of attending include:

Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors

Review clinical results from the DEMAND study

Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies

Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation

Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments  

Key speakers include:

Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis

Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim

James F. List, Vice President, Full Development, Bristol-Myers Squibb

Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca

Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline

Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare

Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London.  Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.   

Benefits of attending include:

Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors

Review clinical results from the DEMAND study

Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies

Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation

Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments  

Key speakers include:

Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis

Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim

James F. List, Vice President, Full Development, Bristol-Myers Squibb

Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca

Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline

Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare

Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London.  Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.   

Benefits of attending include:

Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors

Review clinical results from the DEMAND study

Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies

Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation

Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments  

Key speakers include:

Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis

Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim

James F. List, Vice President, Full Development, Bristol-Myers Squibb

Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca

Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline

Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare